Clinical trial
A Randomized, Open-label, Non-inferiority Phase IIIb Clinical Trial to Evaluate the Immunogenicity Age/Schedule Bridging Between Adolescent Girls Aged 9-14 Years Receiving a 2-dose Regimen or Adolescent Girls Aged 9-17 Years Receiving a 3-dose Regimen of a Quadrivalent Recombinant Human Papillomavirus (HPV) Vaccine (Hansenula Polymorpha) and Women Aged 18-35 Years.
NCT06632912 is registered in ClinicalTrials.gov with National Vaccine and Serum Institute, China as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Open-label, Non-inferiority Phase IIIb Clinical Trial to Evaluate the Immunogenicity Age/Schedule Bridging Between Adolescent Girls Aged 9-14 Years Receiving a 2-dose Regimen or Adolescent Girls Aged 9-17 Years Receiving a 3-dose Regimen of a Quadrivalent Recombinant Human Papillomavirus (HPV) Vaccine (Hansenula Polymorpha) and Women Aged 18-35 Years.
- Lead sponsor
- National Vaccine and Serum Institute, China
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- November 21, 2025
- Completion date
- July 31, 2032
- Enrollment
- 1,800 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
hpv (human papillomavirus)-associated carcinoma, human papillomavirus (hpv) infection